Long-term effectiveness and safety of deucravacitinib for psoriasis: a 52-week real-world study of genital, scalp and nail lesions
Clin Exp Dermatol. 2025 Apr 24;50(5):952-959 doi: 10.1093/ced/llae530. PMID: 39657275.
In a 52-week prospective study, Hagino T, et al. evaluated the real-world effectiveness and safety of deucravacitinib in patients with moderate-to-severe PsO of the genital, scalp and nail regions. They concluded that deucravacitinib treatment for psoriasis demonstrated sustained effectiveness and good tolerability, particularly in difficult-to-treat areas, including the genital, scalp and nail regions.
Keywords:
